Search Within

Shanu Modi

  1. "Molecular Pharmacology and Chemistry Program Faculty"
Formats
  1. Journal Article (21)
  2. Meeting Abstract (19)
  3. Review (1)
Groups
  1. Breast Medicine Service (41)
  2. Department of Medicine (41)
  3. GSK Faculty (41)
  4. Molecular Pharmacology and Chemistry Program Faculty (41)
  5. Sloan Kettering Institute Faculty (41)
  6. Solid Tumor Oncology Division (41)

More Groups

People
  1. Clifford Hudis (21)
  2. Gabriela Chiosis (18)
  3. Neal Rosen (16)
  4. Adriana Dionigi Corben (12)
  5. Tony Taldone (12)
  6. Komal Jhaveri (11)

More People

Years
  1. 2024 (1)
  2. 2023 (1)
  3. 2021 (2)
  4. 2020 (3)
  5. 2019 (6)
  6. 2018 (1)

More Years

Publications
  1. Cancer Research (8)
  2. Journal of Clinical Oncology (7)
  3. Clinical Cancer Research (4)
  4. Breast Cancer Research and Treatment (2)
  5. Clinical Breast Cancer (2)
  6. Nature Communications (2)

More Publications

Publishers
  1. American Association for Cancer Research (13)
  2. American Society of Clinical Oncology (8)
  3. Nature Publishing Group (4)
  4. Cell Press (2)
  5. Elsevier Inc. (2)
  6. Springer (2)

More Publishers

Results (41)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • HSP90 inhibition is effective in breast cancer: A phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab
    Journal Article

    Modi, S.; Stopeck, A.; Linden, H.; Solit, D.; Chandarlapaty, S.; Rosen, N.; D'Andrea, G.; Dickler, M.; Moynahan, M. E.; Sugarman, S.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Using the signature phenotype of inflammatory breast cancer to study dormancy and resistance to therapeutics
    Meeting Abstract

    Corben, A. D.; D'arcy, C.; Modi, S.; Chiosis, G.; Alpaugh, M. L.
    Modern Pathology (2011)

    Fulltext@MSK | Save
  • Advances in the discovery and development of heat-shock protein 90 inhibitors for cancer treatment
    Journal Article

    Patel, H. J.; Modi, S.; Chiosis, G.; Taldone, T.
    Expert Opinion on Drug Discovery (2011)

    Fulltext@MSK | Save
  • Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results
    Journal Article

    Morris, P. G.; Van Poznak, C.; Modi, S.; Mak, A. F.; Patil, S.; Larson, S.; Hudis, C. A.; Divgi, C.; Grewal, R. K.
    Clinical Breast Cancer (2010)

    Fulltext@MSK | Save
  • Phase II trial of the Hsp90 inhibitor tanespimycin (Tan) + trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Kersey, K.; Johnson, R. G.; Rosen, N.; Hannah, A. L.; Hudis, C. A.
    Journal of Clinical Oncology (2008)

    Fulltext@MSK | Save
  • Tanespimycin (17-allylamino-17-demethoxy-geldanamycin; 17-AAG) in breast cancer
    Meeting Abstract

    Modi, S.; Sugarman, S.; Stopeck, A.; Linden, H.; Ma, W.; Chandarlapaty, S.; Solit, D.; Norton, L.; Rosen, N.; Kersey, K.; more...
    Annals of Oncology (2008)

    Fulltext@MSK | Save
  • The heat shock protein 90 chaperone complex: An evolving therapeutic target
    Journal Article

    Barginear, M. F.; Van Poznak, C.; Rosen, N.; Modi, S.; Hudis, C. A.; Budman, D. R.
    Current Cancer Drug Targets (2008)

    Fulltext@MSK | Save
  • Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2-overexpressing breast cancer: A phase I dose-escalation study
    Journal Article

    Modi, S.; Stopeck, A. T.; Gordon, M. S.; Mendelson, D.; Solit, D. B.; Bagatell, R.; Ma, W.; Wheler, J.; Rosen, N.; Norton, L.; more...
    Journal of Clinical Oncology (2007)

    Fulltext@MSK | Save
  • Phase I dose escalating trial of KOS-953 (heat shock protein 90 inhibitor) and trastuzumab (T)
    Meeting Abstract

    Modi, S.; Stopeck, A. T.; Gordon, M. S.; Solit, D.; Bagatell, R.; Ma, W.; Wheler, J.; Cropp, G. F.; Rosen, N.; Johnson, R. G. Jr; more...
    Cancer Research (2006)

    Fulltext@MSK | Save
  • Phase 2 trial of trastuzumab (T) and KOS-953 (17-AAG) in patients (pts) with Her2-positive breast cancer: Preliminary results
    Meeting Abstract

    Modi, S.; Stopeck, A.; Linden, H. M.; Sugarman, S.; Ma, W.; Solit, D.; Rosen, N.; Kersey, K.; Johnson, R. G.; Hannah, A. L.; more...
    Breast Cancer Research and Treatment (2006)

    Fulltext@MSK | Save